BlueWillow’s intranasal vaccine platform has successfully demonstrated safety and immunogenicity in humans in addition to safety and efficacy in primary animal models for several diseases. A successful Phase 1 clinical trial for an Anthrax vaccine candidate was recently completed. Clinical trials for an intranasal Covid-19, HSV-2 and pandemic flu vaccines are planned for the near future.
The company has also demonstrated that its adjuvant technology platform shifts the immune response in food allergy from inflammatory (Th2) to protective (Th1) enabling a durable, intranasal immunotherapy candidate. IND-enabling development is being completed for the lead Peanut Allergy program with clinical trials planned for the near future.